Brief Title
Pulsed Electromagentic Field in Haemophilia
Official Title
Efficacy of Pulsed Electromagnetic Field on Hemarthrotic Knee in Haemophilic Adolescence
Brief Summary
To assess the effect of pulsed electero- magnetic field on swelling, range of motion and
muscle strength of hemarthrotic knee joints of haemophilic subjects.
Detailed Description
Haemophilia is an X-linked hereditary sex recessive disorder that impairs the body's ability
to make blood clots. It includes two types: A (FVIII deficit factor) and B (IX deficit
factor), depending on FVIII/FIX percentage in blood. The severity of haemophilia is
classified into (severe: <1%, moderate: 1-5%, and mild: >5%). The prevalence of haemophilia A
is 1: 5000 live births and haemophilia B is 1: 30000 live births.
This disease is characterized by hemarthrosis which is a hemorrhage in the locomotor system,
mainly muscles and joints. Joint bleeding mainly occurs in knees, ankles and elbows.
Haemorrhage in the muscle or joints accounts for 80% to 90% of all bleeding episodes in
people with haemophilia. The most commonly affected joints in non-prophylaxis patients are
the knees (45%) which is thought to be due to the large size of the synovial membrane and
large rotational forces present. It is followed by the elbows (30%), ankles (15%), shoulders
(3%), and wrists (2%). Bleeds are best detected by the patients themselves as bruising and
swelling or described as a feeling of warmth or tingling within the joint preceding the
clinical signs.
Pulsed electromagnetic field (PEMF) has been reported to be effective in reducing pain,
healing of ulcers and promote bone healing, and treating osteoarthritis and inflammatory
diseases of the musculoskeletal system. Also, it was reported that PEMF exposure
significantly increases the anti-inflammatory effect, suggesting its potential therapeutic
use in the treatment of inflammatory bone and joint disorders.
Study Type
Interventional
Primary Outcome
swelling
Secondary Outcome
range of motion
Condition
Hemophilia A
Intervention
PEMF
Study Arms / Comparison Groups
Placebo group
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
30
Start Date
September 1, 2020
Completion Date
December 19, 2020
Primary Completion Date
December 19, 2020
Eligibility Criteria
Inclusion Criteria:
- type A hemophilia (moderate)
- free from any musculoskeletal deformities.
Exclusion Criteria:
- patients who performed surgical procedures 6 weeks before conducting the study
Gender
Male
Ages
13 Years - 16 Years
Accepts Healthy Volunteers
No
Contacts
Hala I. Kassem, Professor, ,
Location Countries
Egypt
Location Countries
Egypt
Administrative Informations
NCT ID
NCT04590456
Organization ID
PEMF
Responsible Party
Principal Investigator
Study Sponsor
Delta University for Science and Technology
Study Sponsor
Hala I. Kassem, Professor, Study Chair, Professor of physical therapy
Verification Date
December 2020